Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.33. Which is the better fit depends on your goals.
| BBIO | VWO | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | — |
52-Week High | $90.17 | $61.24 |
52-Week Low | $47.29 | $51.20 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
